ID

38045

Description

Predictors of Response to Neoadjuvant Docetaxel-Carboplatin Chemotherapy for Patients With Stage II and III Triple Negative Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01560663

Lien

https://clinicaltrials.gov/show/NCT01560663

Mots-clés

Versions (1)
  1. 11/09/2019 11/09/2019 -
Détendeur de droits

See clinicaltrials.gov

Téléchargé le

11 septembre 2019

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Breast Cancer NCT01560663

Anglais

Eligibility Breast Cancer NCT01560663

1 Formulaires  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
informed consent form signed by the patient to accept study enrollment.
Description

Informed Consent

Type de données

boolean

Alias
UMLS CUI [1]
C0021430
female with pathologically confirmed diagnosis of primary invasive operable breast cancer, stage iia-iiic (6th edition of the ajcc cancer staging manual), with tumors ≥
Description

Gender | Invasive carcinoma of breast Operable TNM Breast tumor staging

Type de données

boolean

Alias
UMLS CUI [1]
C0079399
UMLS CUI [2,1]
C0853879
UMLS CUI [2,2]
C0205188
UMLS CUI [2,3]
C0474926
2cm.
Description

Tumor size

Type de données

boolean

Alias
UMLS CUI [1]
C0475440
triple negative phenotype patients (re and pr of less than 1% of stained cells by ihq, ihc for her2 of 0-1+ or ish negative if 2/3+), according to local laboratory.
Description

Triple Negative Breast Neoplasm | Estrogen Receptor Measurement Immunohistochemistry | Progesterone Receptor Measurement Immunohistochemistry | HER2 Immunohistochemistry | HER2 ISH Negative

Type de données

boolean

Alias
UMLS CUI [1]
C3539878
UMLS CUI [2,1]
C3811131
UMLS CUI [2,2]
C0021044
UMLS CUI [3,1]
C3889640
UMLS CUI [3,2]
C0021044
UMLS CUI [4,1]
C0069515
UMLS CUI [4,2]
C0021044
UMLS CUI [5,1]
C0069515
UMLS CUI [5,2]
C3853647
UMLS CUI [5,3]
C1513916
age 18-75 years.
Description

Age

Type de données

boolean

Alias
UMLS CUI [1]
C0001779
adequate performance status (ecog <2).
Description

ECOG performance status

Type de données

boolean

Alias
UMLS CUI [1]
C1520224
adequate renal and liver function and bone marrow reserve.
Description

Renal function | Liver function | Bone Marrow Mature Neutrophils Present

Type de données

boolean

Alias
UMLS CUI [1]
C0232804
UMLS CUI [2]
C0232741
UMLS CUI [3,1]
C0005953
UMLS CUI [3,2]
C1708947
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
clinical or radiologic evidence of metastatic disease.
Description

Neoplasm Metastasis

Type de données

boolean

Alias
UMLS CUI [1]
C0027627
prior or concurrent anti-cancer therapy for current disease (hormone therapy, chemotherapy, radiotherapy, immunotherapy).
Description

Cancer treatment Disease Current | Hormone Therapy | Chemotherapy | Therapeutic radiology procedure | Immunotherapy

Type de données

boolean

Alias
UMLS CUI [1,1]
C0920425
UMLS CUI [1,2]
C0012634
UMLS CUI [1,3]
C0521116
UMLS CUI [2]
C0279025
UMLS CUI [3]
C0392920
UMLS CUI [4]
C1522449
UMLS CUI [5]
C0021083
prior therapy with taxanes, anthracyclines or carboplatin for any malignancy.
Description

Cancer treatment Previous | taxane | Anthracyclines | Carboplatin

Type de données

boolean

Alias
UMLS CUI [1,1]
C0920425
UMLS CUI [1,2]
C0205156
UMLS CUI [2]
C0215136
UMLS CUI [3]
C0282564
UMLS CUI [4]
C0079083
contraindication for study drugs (docetaxel or carboplatin).
Description

Medical contraindication Investigational New Drugs | Medical contraindication Docetaxel | Medical contraindication Carboplatin

Type de données

boolean

Alias
UMLS CUI [1,1]
C1301624
UMLS CUI [1,2]
C0013230
UMLS CUI [2,1]
C1301624
UMLS CUI [2,2]
C0246415
UMLS CUI [3,1]
C1301624
UMLS CUI [3,2]
C0079083
serious concomitant systemic disorder that in the opinion of the investigator would compromise the patient's ability to complete the study, or have any other disease that could be worsened by chemotherapy or other potential support therapies.
Description

Comorbidity Systemic Serious | Comorbidity compromises Completion of clinical trial | Disease Worsening Due to Chemotherapy | Disease Worsening Due to Adjuvant therapy

Type de données

boolean

Alias
UMLS CUI [1,1]
C0009488
UMLS CUI [1,2]
C0205373
UMLS CUI [1,3]
C0205404
UMLS CUI [2,1]
C0009488
UMLS CUI [2,2]
C2945640
UMLS CUI [2,3]
C2732579
UMLS CUI [3,1]
C0012634
UMLS CUI [3,2]
C0332271
UMLS CUI [3,3]
C0678226
UMLS CUI [3,4]
C0392920
UMLS CUI [4,1]
C0012634
UMLS CUI [4,2]
C0332271
UMLS CUI [4,3]
C0678226
UMLS CUI [4,4]
C0677850
Retour au début de la page

Similar models

Eligibility Breast Cancer NCT01560663

1 Formulaires
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
C1512693 (UMLS CUI)
Informed Consent
Item
informed consent form signed by the patient to accept study enrollment.
boolean
C0021430 (UMLS CUI [1])
Gender | Invasive carcinoma of breast Operable TNM Breast tumor staging
Item
female with pathologically confirmed diagnosis of primary invasive operable breast cancer, stage iia-iiic (6th edition of the ajcc cancer staging manual), with tumors ≥
boolean
C0079399 (UMLS CUI [1])
C0853879 (UMLS CUI [2,1])
C0205188 (UMLS CUI [2,2])
C0474926 (UMLS CUI [2,3])
Tumor size
Item
2cm.
boolean
C0475440 (UMLS CUI [1])
Triple Negative Breast Neoplasm | Estrogen Receptor Measurement Immunohistochemistry | Progesterone Receptor Measurement Immunohistochemistry | HER2 Immunohistochemistry | HER2 ISH Negative
Item
triple negative phenotype patients (re and pr of less than 1% of stained cells by ihq, ihc for her2 of 0-1+ or ish negative if 2/3+), according to local laboratory.
boolean
C3539878 (UMLS CUI [1])
C3811131 (UMLS CUI [2,1])
C0021044 (UMLS CUI [2,2])
C3889640 (UMLS CUI [3,1])
C0021044 (UMLS CUI [3,2])
C0069515 (UMLS CUI [4,1])
C0021044 (UMLS CUI [4,2])
C0069515 (UMLS CUI [5,1])
C3853647 (UMLS CUI [5,2])
C1513916 (UMLS CUI [5,3])
Age
Item
age 18-75 years.
boolean
C0001779 (UMLS CUI [1])
ECOG performance status
Item
adequate performance status (ecog <2).
boolean
C1520224 (UMLS CUI [1])
Renal function | Liver function | Bone Marrow Mature Neutrophils Present
Item
adequate renal and liver function and bone marrow reserve.
boolean
C0232804 (UMLS CUI [1])
C0232741 (UMLS CUI [2])
C0005953 (UMLS CUI [3,1])
C1708947 (UMLS CUI [3,2])
Item Group
C0680251 (UMLS CUI)
Neoplasm Metastasis
Item
clinical or radiologic evidence of metastatic disease.
boolean
C0027627 (UMLS CUI [1])
Cancer treatment Disease Current | Hormone Therapy | Chemotherapy | Therapeutic radiology procedure | Immunotherapy
Item
prior or concurrent anti-cancer therapy for current disease (hormone therapy, chemotherapy, radiotherapy, immunotherapy).
boolean
C0920425 (UMLS CUI [1,1])
C0012634 (UMLS CUI [1,2])
C0521116 (UMLS CUI [1,3])
C0279025 (UMLS CUI [2])
C0392920 (UMLS CUI [3])
C1522449 (UMLS CUI [4])
C0021083 (UMLS CUI [5])
Cancer treatment Previous | taxane | Anthracyclines | Carboplatin
Item
prior therapy with taxanes, anthracyclines or carboplatin for any malignancy.
boolean
C0920425 (UMLS CUI [1,1])
C0205156 (UMLS CUI [1,2])
C0215136 (UMLS CUI [2])
C0282564 (UMLS CUI [3])
C0079083 (UMLS CUI [4])
Medical contraindication Investigational New Drugs | Medical contraindication Docetaxel | Medical contraindication Carboplatin
Item
contraindication for study drugs (docetaxel or carboplatin).
boolean
C1301624 (UMLS CUI [1,1])
C0013230 (UMLS CUI [1,2])
C1301624 (UMLS CUI [2,1])
C0246415 (UMLS CUI [2,2])
C1301624 (UMLS CUI [3,1])
C0079083 (UMLS CUI [3,2])
Comorbidity Systemic Serious | Comorbidity compromises Completion of clinical trial | Disease Worsening Due to Chemotherapy | Disease Worsening Due to Adjuvant therapy
Item
serious concomitant systemic disorder that in the opinion of the investigator would compromise the patient's ability to complete the study, or have any other disease that could be worsened by chemotherapy or other potential support therapies.
boolean
C0009488 (UMLS CUI [1,1])
C0205373 (UMLS CUI [1,2])
C0205404 (UMLS CUI [1,3])
C0009488 (UMLS CUI [2,1])
C2945640 (UMLS CUI [2,2])
C2732579 (UMLS CUI [2,3])
C0012634 (UMLS CUI [3,1])
C0332271 (UMLS CUI [3,2])
C0678226 (UMLS CUI [3,3])
C0392920 (UMLS CUI [3,4])
C0012634 (UMLS CUI [4,1])
C0332271 (UMLS CUI [4,2])
C0678226 (UMLS CUI [4,3])
C0677850 (UMLS CUI [4,4])
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial